(Q37275504)

19 August 2017

Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease (English)

1 reference

19 August 2017

0 references

1 reference

1 reference

1 reference

William Jeffery Sandborn

7

object named as

W J Sandborn

1 reference

19 August 2017

8

B G Feagan

1 reference

19 August 2017

M Rosario

1

1 reference

19 August 2017

N L Dirks

2

1 reference

19 August 2017

M R Gastonguay

3

1 reference

19 August 2017

A A Fasanmade

4

1 reference

19 August 2017

T Wyant

5

1 reference

19 August 2017

A Parikh

6

1 reference

19 August 2017

W Reinisch

9

1 reference

19 August 2017

I Fox

10

1 reference

19 August 2017

language of work or name

English

0 references

publication date

20 May 2015

1 reference

Alimentary Pharmacology & Therapeutics

19 August 2017

1 reference

19 August 2017

42

1 reference

19 August 2017

2

1 reference

19 August 2017

188-202

1 reference

Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis.

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5032981

Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5032981

Vedolizumab as induction and maintenance therapy for Crohn's disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5032981

Vedolizumab as induction and maintenance therapy for ulcerative colitis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5032981

Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5032981

Therapeutic drug monitoring of biologics for inflammatory bowel disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5032981

Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5032981

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5032981

The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5032981

Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5032981

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5032981

Elimination mechanisms of therapeutic monoclonal antibodies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5032981

Clinical pharmacokinetics of TNF antagonists: how do they differ?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5032981

Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5032981

Population pharmacokinetics of infliximab in patients with ankylosing spondylitis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5032981

Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5032981

Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactions.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5032981

Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5032981

Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5032981

Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5032981

Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5032981

Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5032981

Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5032981

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5032981

Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study

3 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25996351

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/APT.13243

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

25996351

1 reference